01 — At a Glance
The Pharma Outsourcing Shop That Just Became a Unicorn on NSE
- 52-Week High / Low₹1,084 / ₹635
- Full-Year FY25 Revenue₹1,695 Cr
- Full-Year FY25 PAT₹170 Cr
- Q3 FY26 EPS₹4.75
- Annualised EPS (Q3×4)₹19.0
- Book Value (Per Share)₹107
- Price to Book9.42x
- Dividend Yield0.00%
- Debt / Equity0.22x
- ROCE (TTM)14.0%
Reality Check: Sai Life Sciences IPO’d in December 2024 and has spent the last two months proving every analyst bulletin point correct. Q3 FY26 revenue hit ₹556 crore (+27% YoY), PAT at ₹100 crore (+86% YoY), and TTM revenue is already at ₹2,170 crore running at 40% growth. The stock now trades at 63x earnings—a 2.4x premium to the pharma sector median P/E of 27.3x. Welcome to high-growth smallcaps where 60% ROCE is the entry condition and 100% PAT swings don’t raise an eyebrow.
02 — Introduction
Outsource Your Science to India. That’s It. That’s the Business Model.
Sai Life Sciences is a CRDMO—which is nerd-speak for “Contract Research, Development, and Manufacturing Organization.” Forget Silicon Valley’s app-startup fetish. In biotech’s actual money-printing machine, the real action is pharma companies (especially the big 500-million-dollar biotech startups in Boston) outsourcing their drug discovery and manufacturing to cost-effective, world-class Indian labs.
Founded in 1999, went public in December 2024 at ₹600/share. Today at ₹1,009. The IPO was positioned as one of the hottest biotech exits in 15 years. For context: the company went from a net loss of ₹14 crore in Jun 2024 (a single quarter) to a PAT of ₹170 crore for the full FY25. The margin expansion is not just linear—it’s exponential. And the market is pricing it like every quarter will be another 86% profit swing.
Here’s the honest bit: pharma outsourcing to India is not sexy. It’s also the most recession-resistant micro-narrative in Indian equities. When biotech money dries up in the US, funding gets tighter, and venture capitalists get less crazy—they still need drug discovery. They still need manufacturing. They just outsource more aggressively to cut costs. Sai Life Sciences is the beneficiary of a global “China+1” and “India for nearshoring” mega-trend that will last 20 years.
The real question: Is 63x earnings really fair for a company earning 14% ROCE (best-in-sector is 27%+) and re-investing every rupee of profit back into expansion? Let’s dig in.
Management Concall (Feb 2026): “Tracking ahead of plan… strategic conversations with large global pharma innovators.” The company expects to sustain 28–30% EBITDA margins even while spending ₹700 crore capex this year. This is either confidence bordering on delusion, or they know something about their pharma relationships that models can’t see yet.
03 — Business Model: Turn Talent Into Margin
The Lab Costs ₹500 Cr. The Scientists Cost ₹10 Cr. The Margin? Infinite.
Sai Life Sciences operates two revenue buckets: Discovery (CRO) and Manufacturing (CDMO). Discovery generates 35–40% of revenues and involves chemistry, pharmacology, DMPK, toxicology studies for early-stage drug discovery. CDMO generates 60–65% and handles process development, API manufacturing, clinical supplies, and commercial-scale production.
Geography: 99% of revenues are exports. That’s right. Three facilities in Hyderabad and Bidar, one in Boston, one in Manchester—entirely serving US and European pharma. The cost arbitrage is criminal. A medicinal chemist in Boston costs ₹2 crore annually. The exact same PhD from IIT in Hyderabad costs ₹30 lakh. Sai Life employs 3,400+ scientists across these centres and is hiring furiously into peptides, ADCs (antibody-drug conjugates), oligonucleotides, and AI-enabled drug discovery.
Customer base: 300+ active clients including 18 of the top 25 global pharma companies. Top customer is 12% of revenue (good diversification for this sector). They’ve launched 30+ commercial molecules to market and have 160+ in early-stage pipelines. The CDMO segment (manufacturing) already derives 91% of revenues from large pharma (vs. biotech). This is THE structural shift that offsets the US biotech funding crisis everyone fears.
Discovery Revenue35-40%CRO Mix
Manufacturing Revenue60-65%CDMO Mix
Large Pharma Mix91%CDMO Revenue
Export Revenue %99%Hardcore Global
Tech Stack: AI-driven retrosynthesis tools, photochemical platforms, electrochemical synthesis, automation everywhere. The company is building an “AI-first roadmap” with external partnerships to let scientists spend more time on “high-value science.” Translation: we’re automating the repetitive drudgery so your PhD doesn’t waste 40% of their day on desk work.
💬 Real talk: If big pharma keeps outsourcing to India for cost, and Sai keeps hiring science talent aggressively—who actually captures the margin? The American customer or the Indian operator?
04 — Financials Overview
Q3 FY26: The Explosive Numbers Everyone’s Justifying
Result type: Quarterly Results (Q3 FY26 = Dec 2025) | Q3 FY26 EPS: ₹4.75 | Annualised EPS (Q3×4): ₹19.0 | Full-Year FY25 EPS: ₹8.16
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 556 | 440 | 537 | +26.5% | +3.5% |
| Operating Profit (EBITDA) | 191 | 124 | 146 | +54.0% | +30.8% |
| OPM % | 34% | 28% | 27% | +600 bps | +700 bps |
| PAT | 100 | 54 | 84 | +86.0% | +19.0% |
| EPS (₹) | 4.75 | 2.59 | 4.00 | +83.4% | +18.8% |
P/E Math: Annualised Q3 EPS (₹4.75 × 4) = ₹19.0. CMP ₹1,009 ÷ ₹19.0 = P/E 53x on annualised basis. Full-year FY25 EPS ₹8.16 ÷ ₹1,009 = P/E 123.8x on FY25 earnings (ancient history by growth-stock standards). The market is clearly pricing 9M FY26 growth (₹245 crore PAT on +199% YoY) as permanent. One bad quarter—or any sign of stalling—and watch the repricing happen in 48 hours.
05 — Valuation Discussion — Fair Value Range
Is ₹1,009 a Deal or a Trap? Three Ways to Think About It.
Join 10,000+ investors who read this every week.
